Kornimate/medical-research-clean huggingface dataset:
a study of n-acetylcysteine in patients with covid-19 infection

Conditions: Covid-19

Summary: the study researchers think that a medication called n-acetylcysteine can help fight the covid-19 virus by boosting a type of cell in your immune system that attacks infections. by helping your immune system fight the virus, the researchers think that the infection will get better, which could allow the patient to be moved out of the critical care unit or go off a ventilator, or prevent them from moving into a critical care unit or going on a ventilator. the us food and drug administration (fda) has approved n-acetylcysteine to treat the liver side effects resulting from an overdose of the anti-inflammatory medication tylenol® (acetaminophen). n-acetylcysteine is also used to loosen the thick mucus in the lungs of people with cystic fibrosis or chronic obstructive pulmonary disease (copd). this study is the first to test n-acetylcysteine in people with severe covid-19 infections.


Eligibility criteria:
inclusion criteria: * documented covid-19 infection (either performed on site or documented external report) * age ≥ 18 arm a: * admission to an intensive care unit at msk (m-11) and/or receiving mechanical ventilation * absolute lymphocyte count ≤ 1.0/mm3 * as the alc of patients with lymphoid malignancies is unreliable, they may be enrolled at the discretion of the treating physician after review of their blood work. arm b: * arm b:requiring 2l or more of supplemental oxygen by nasal cannula or higher to maintain spo2 of 95% exclusion criteria: arm b: * requiring mechanical ventilation or admission to an intensive care unit at msk (m11)

Keywords: n-acetylcysteine 20-168
factors associated with postoperative strabismus after floor fracture repair

Conditions: Orbital Fractures; Strabismus

Summary: in patients suffered from floor fractures, there are 21.9% complaining about diplopia before fracture repair surgery and 20.8% after operation. even after 6 months, there still are 16.4% had similar conditions. investigators are planned to find predicting factors to prevent such conditions from happening.


Eligibility criteria:
inclusion criteria: * patients suffering from floor fractures in tri-service general hospital in past 10 years. exclusion criteria: * prior ocular surgeries * multiple facial trauma or facial bone fractures

Keywords: orbital fractures strabismus predicting factors orbital floor fractures
combined ex-press implantation alone or with phacoemulsification for glaucoma associated with cataract

Conditions: Glaucoma and Ocular Hypertension

Summary: a prospective study reporting on ex-press shunt implantation alone or combined cataract and glaucoma surgery.

the occurrence of both glaucoma and clinically relevant cataract in the same individual is a frequent condition, especially in the elderly population. besides age, this might be related to the possible role of antiglaucoma medications in the progression of lens opacity.when both procedures are required, these can be performed separately or in combination. glaucoma filtering surgery is indicated when glaucomatous damage progresses despite the lower level of intraocular pressure (iop) obtained with pharmacological and/or laser treatment. the ex-press is a miniature stainless steel glaucoma device, developed as an alternative to trabeculectomy and to the other types of glaucoma filtering surgery for patients with poag. this procedure would be theoretically more reproducible and simple to perform as well as less traumatic to the ocular tissue than traditional filtering surgery. the implant is inserted at the limbus under a conjunctival flap and diverts the aqueous humour from the anterior chamber to the subconjunctival space, obtaining the formation of a conjunctival filtration bleb, in a similar way to trabeculectomy. this procedure can be performed on its own or in combination with phacoemulsification. this study is aimed to test the efficacy and saftey of ex-press shunt implantation alone or combined cataract and glaucoma surgery in patients with medically uncontrolled glaucoma and cataract .

Eligibility criteria:
inclusion criteria: - age above 18 exclusion criteria: - congenital glaucoma
appraise 2.0: live trial of the appraise trauma decision support system

Conditions: Wounds and Injuries

Summary: this is a pilot evaluation of the appraise trauma decision-support software system ("the system"). the specific objections are as follows: 1. evaluate the robustness of the system (i.e., whether the software performs in real-time in accordance with a priori technical specifications during real-time clinical use); 2. evaluate whether the real-time display of the system causes distraction or confusion to clinicians treating the trauma patient such that its risks exceed its benefits; 3. collect pilot data to allow for a statistical power analysis to design a future clinical trial evaluating efficacy.


Eligibility criteria:
inclusion criteria: * adult (≥18 yrs) emergency department (ed) patient * triaged to the "acute" area of the ed. (the "acute" area is the designated area for ed patients with potential or established critical illness. triage to acute is a routine ed operation that is performed based on departmental guidelines and the professional judgement of an experienced triage nurse). * clinical concern for acute injury (based on either an explicitly chief complaint of acute injury, or clinical team with documented concern for acute injury as a relevant part of patient presentation). exclusion criteria: * prisoners * patients known to be pregnant, based on patient report, physical exam, or bedside ultrasound * patients wearing an "efic opt-out" bracelet * any concern about the suitability of the software system for a specific patient by any clinician involved in the patient's ed care, or by the patient themselves (or by any lar \[lawfully authorized representative\] of the patient).
make it clean, impact of pocket revision on the rate of infection and other complications in patients requiring pocket manipulation for generator replacement and/or lead replacement or revision: a prospective randomized study

Conditions: Infection

Summary: to determine the effect of scar tissue removal on the rate of infection and any other complications such as bleeding in patients with an icd or pacemaker who have the device generator or leads replaced or repositioned.

this is a randomized, prospective, single-blind study that evaluates the effect of removal of scar tissue during pacemaker/icd pocket revision on infection and complications. subjects will be randomly assigned to either removal of the scar tissue surrounding the implanted device during device replacement or to device replacement without removal of this tissue. subjects will be followed for one year post-procedure for the occurrence of infection, bleeding/hematoma, or other complications.

Eligibility criteria:
inclusion criteria: 1. age 18 years or greater 2. willingness to provide written informed consent 3. subjects presenting for any of the following: 1. pacemaker/icd generator change 2. pacemaker/icd lead replacement 3. pacemaker/icd lead revision 4. pacemaker/icd upgrades exclusion criteria: 1. age less than 18 years 2. unwillingness to provide written informed consent 3. subjects unable to give consent 4. pregnant or nursing women 5. patients who have undergone pocket revision or manipulation less than 365 days prior 6. patients who have undergone pacemaker or icd implantation less than 365 days prior

Keywords: cardiac pacemaker, artificial
comparative efficacy of lidocaine spray versus vaginal dinoprostone in iud insertion

Conditions: Contraception

Summary: the aim of this study is to compare the safety and efficacy of lidocaine spray versus vaginal dinoprostone in relieving pain during levonorgestrel iud insertion in nulliparous women


Eligibility criteria:
inclusion criteria: * nulliparous women requesting levonorgestrel iud insertion exclusion criteria: * multiparous women, allergy or contraindication to study drugs or contraindications to lng-iud insertion
dry age-related macular degeneration (amd) treatment with rheopheresis trial

Conditions: Dry Age Related Macular Degeneration

Summary: purpose is to evaluate rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.


Eligibility criteria:
inclusion criteria: * 50 to 85 years old * diagnosis of amd in both eyes * must have dry amd in the study eye * study eyes with best-corrected etdrs-visual acuity of 0.1-0.8 * peripheral veins allowing vascular access to establish the extracorporal circuit. exclusion criteria: * other retinal or choroidal disorders than amd * optic nerve disease, glaucoma * conditions that limit the view of the fundus * acute bleeding in any eye general exclusion criteria for the treatment of rheopheresis: * anaemia * haemorrhagic diathesis or coagulopathy * diabetes * serious acute or chronic kidney or liver failure * hypotension systolic \< 100 mmhg * chronic viral infection (hiv, hepatitis b, c) * epilepsia, psychosis or dementia * a malignant disease or any other condition with life expectancy \< 12 months * known history of alcohol or drug abuse and long term serious nicotine abuse

Keywords: rheopheresis dry age related macular degeneration amd apheresis microcirculation
tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis - ecztra 6 (eczema tralokinumab trial no. 6).

Conditions: Atopic Dermatitis

Summary: primary objective: to evaluate the efficacy of subcutaneous (sc) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to \<18 years) with moderate-to-severe ad. secondary objectives: to evaluate the efficacy of tralokinumab on severity and extent of ad, itch, and health-related quality of life compared with placebo. to investigate the safety, immunogenicity, and tolerability of sc administration of tralokinumab compared with placebo when used to treat adolescent subjects (age 12 to \<18 years) with moderate-to-severe ad.


Eligibility criteria:
inclusion criteria: * age 12 to 17. * diagnosis of ad as defined by the hanifin and rajka (1980) criteria for ad. * history of ad for ≥1 year. * history of topical corticosteroid (tcs; europe: class 3 or higher; us: class 4 or lower) and/or topical calcineurin inhibitor (tci) treatment failure or subjects for whom these topical ad treatments are medically inadvisable. * ad involvement of ≥10% body surface area at screening and baseline. * stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation. exclusion criteria: * active dermatologic conditions that may confound the diagnosis of ad. * use of tanning beds or phototherapy within 6 weeks prior to randomisation. * treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation. * treatment with tcs, tci, or topical phosphodiesterase 4 (pde-4) inhibitor within 2 weeks prior to randomisation. * receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin e) including dupilumab or investigational biologic agents. * active skin infection within 1 week prior to randomisation. * clinically significant infection within 4 weeks prior to randomisation. * a helminth parasitic infection within 6 months prior to the date informed consent is obtained. * tuberculosis requiring treatment within the 12 months prior to screening. * known primary immunodeficiency disorder.
advair® diskus® inhaler (fluticasone propionate/salmeterol) versus serevent® diskus® inhaler (salmeterol) for the treatment of chronic obstructive pulmonary disease exacerbations. advair® diskus® inhaler and serevent® diskus® inhaler are trademarks of the gsk group of companies.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study evaluates the effect of two medicines on copd (chronic obstructive pulmonary disease) exacerbations. this study will last up to 56 weeks, and subjects will visit the clinic 10 times. subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. all study related medicines and medical examinations will be provided at no cost. the two drugs used in this study have been approved by the fda for use in patients with copd.

a randomized, double-blind, parallel group, 52-week study to compare the effect of the fluticasone propionate/salmeterol diskus® inhaler combination product 250/50mcg twice daily (bid) with salmeterol diskus® inhaler 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (copd)

Eligibility criteria:
inclusion criteria: * diagnosis of copd (chronic obstructive pulmonary disease). * current or previous cigarette smokers with a smoking history of at least 10 pack-years. * history of a least 1 copd exacerbation in the 12 months prior to screening. * forced expiratory volume in one second (fev1) of less than or equal to 50% of predicted normal. exclusion criteria: * current diagnosis of asthma. * additional respiratory disorders other than copd (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis). * concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and anti-leukotrienes. * lung resection surgery within 1 year of screening. * abnormal and clinically significant ecg findings at screening. * other inclusion and exclusion criteria will be evaluated at the first study visit.

Keywords: exacerbations breathing chronic obstructive pulmonary disease
optimization of nutritional management of patients waiting for lung transplant into strasbourg university hospitals

Conditions: Malnutrition

Summary: undernutrition is the result of energy and protein deficiency and / or catabolic. these phenomena are observed daily in patients awaiting lung transplantation. after lung transplantation that undernutrition is growing (on average 11% weight loss after the first observations in the continuing care of the university hospital of strasbourg). in other words the non-malnourished patients become. hence the importance to reach every patient awaiting transplant, mainly to patients already malnourished before surgery. several studies have shown that early nutritional support has a direct effect on reducing comorbidities and the average length of stay. in the course of care of these patients it is necessary to intensify the dietary management to give them the best chance for early rehabilitation. the main objective of the study is to evaluate the impact of the use of the sfnep's nutritional care decision-making tree (société francophone nutrition clinique et métabolisme) on the implementation of enteral nutrition by gastrostomy tube in patients awaiting for lung transplantation.


Eligibility criteria:
inclusion criteria: transplant patients between january 1, 2012 and december 31, 2015 aged over 16 years, with a bmi \<25 at the time of pre-transplant assessment and that not oppose the use of his data. exclusion criteria: * cardiopulmonary transplant patients * refusal to participate in the study

Keywords: malnutrition undernutrition lung transplantation artificial nutrition nutritional supplements enteral nutrition
digital limited interaction efficacy trial of lifeskills mobile to reduce hiv incidence in ytw

Conditions: HIV Prevention

Summary: the lifeskills mobile app will be evaluated in a randomized controlled trial (rct) among 5,000 young transgender women (ytw), ages 16-29 in the united states (u.s.). study findings will demonstrate if the intervention will reduce hiv incidence.

lifeskills mobile is an mhealth intervention to promote biobehavioral hiv prevention strategies based on empowerment theory and was developed using a community-based participatory research approach. an rct assesses the efficacy of the lifeskills mobile intervention in comparison to a standard of care (soc) condition among 5,000 ytw recruited online. at baseline and every 6 months through 12-48 months (depending on when the participant enrolled), enrolled participants will complete an online survey sent via a link to their mobile phone and will be mailed an oraquick in-home hiv test kit. we will also estimate the total and incremental costs of the lifeskills mobile intervention relative to soc, from healthcare sector and societal perspectives.

Eligibility criteria:
inclusion criteria: * self-identified as transgender, woman, and/or along the feminine spectrum with a male assigned sex at birth * ages 16-29 * hiv uninfected at enrollment visit, verified via hiv home test kit * self-reported lifetime history of condomless sex or recent history of sex (anal or vaginal in the past 12 months) * able to speak/understand english * owns a smartphone or home computer or willing to use one in the study * willing and able to provide informed consent/assent exclusion criteria: * unable to provide informed consent due to severe mental or physical illness, or substance intoxication at time of enrollment * discovery of active suicidal ideation or major mental illness (e.g. untreated psychosis or mania) at the time of the interview (these patients will be referred immediately for treatment, but may join the study when this is resolved) * a positive home hiv test kit result at baseline; these individuals will be immediately linked to hiv clinical care in their local areas.

Keywords: transgender women (tgw) prep mhealth hiv prevention sexual behavior
use of 1 minute sit to stand test for physical capacity and effort related desaturation in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the aim of this study is to investigate the usability of the 1 minute sit to stand test (1 msts) in evaluating physical capacity and effort-related desaturation in individuals with amyotrophic lateral sclerosis (als). in this context, patients diagnosed with als who meet the inclusion criteria will be included in the study. for the physical capacity assessment of patients with als at different ambulatory levels included in this study, a 6 minutes walking test (6 mwt) and a 1 msts will be applied. before and at the end of the test, the severity of dyspnea and leg fatigue of the patients will be determined by the modified borg scale; effort-induced desaturation and heart rate by fingertip pulse oximetry; peripheral muscle strength (for the quadriceps femoris muscle) will be evaluated with a hand held dynamometer. when the studies are examined, it has been determined that the 6 mwt is relatively difficult to tolerate in individuals with als, it may be difficult to provide the necessary space and equipment for the test, and a shorter, easy-to-apply, and practical evaluation method that can be used instead of this test in the clinic is needed. as a result of this study, the usability of the 1 msts in individuals with ambulatory als in evaluating physical capacity and desaturation due to effort will be revealed.


Eligibility criteria:
inclusion criteria: * diagnosed with als * 18 years and over * ambulatory * volunteer to participate in the study exclusion criteria: * having a comorbidity that may affect the results of the study (orthopedic, cardiopulmonary, orthopedic, psychiatric, etc.) * not willing to participate in the study

Keywords: amyotrophic lateral sclerosis physical capacity desaturation dyspne
safety and pharmacokinetic characteristics of dkf-313

Conditions: Benign Prostate Hyperplasia; Healthy

Summary: this is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of dkf-313 (dutasteride and tadalafil) in healthy male volunteers.

this study is conducted to evaluate the pharmacokinetics of dkf-313 (dutasteride and tadalafil) comparing with the concomitant administration of avodart and cialis in healthy male volunteers.

Eligibility criteria:
inclusion criteria: 1. age 19 to 29 years 2. bmi 17.5 to 30.5 kg/m2 and body weight 55 kg or more 3. no congenital or chronic diseases within 3 years, no disease symptoms or findings 4. eligible according to the laboratory results of hematology, blood chemistry and urinalysis and ecg 5. voluntarily signed the informed consent form 6. willing to participate in the study exclusion criteria: 1. clinically significant disorders of blood, kidney, endocrine, respiratory system, gastrointestinal system, urology, cardiovascular system, liver, psychiatry, neurology or allergy 2. gastrointestinal diseases or surgery which may affect absorption of the investigational products 3. alt or ast \> 2xuln 4. excessive alcohol consumption (\> 210 g/week) within 6 months 5. participated and administered the investigational products in other clinical trial within 2 months 6. sbp ≤ 100 mmhg or ≥ 150 mmhg or dbp ≤ 60 mmhg or ≥ 100 mmhg 7. history or positive result of serious alcohol or drug abuse within 1 year 8. drugs which induce or inhibit drug metabolism within 1 month 9. smoked more than 10 cigarettes a day 10. prescribed drugs or over-the counter drugs within 10 days 11. donated whole blood within 2 months or apheresis within 1 month 12. severe acute/chronic medical and mental conditions or lab abnormalities which may increase the risk or interfere in the interpretation of study results 13. hypersensitivity to tadalafil or phosphodiesterase type 5 inhibitor, and dutasteride or 5-α reductase inhibitor, or other drugs including aspirin, antibiotics, etc. 14. galactose intolerance, fructose intolerance, lapp lactase deficiency, glucose-galactose malabsorption 15. cyp3a4 inhibitors or cyp3a4 inducers within 2 weeks 16. myocardial infarction within 90 days 17. unstable angina or angina during sexual intercourse 18. heart failure (new york heart association class 2 or higher) within 6 months 19. uncontrolled arrhythmias 20. stroke within 6 months 21. inherited retinal degeneration including retinitis pigmentosa 22. vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (naion) 23. plans to donate blood for at least 6 months after final dose of the investigational products 24. unwilling to comply with the lifestyle guidelines in the protocol 25. not eligible due to other reasons at the investigator's discretion
study evaluating effexor xr for major depression.

Conditions: Depression

Summary: study evaluating effexor xr for major depression.


Eligibility criteria:
inclusion criteria: * patients diagnosed with major depression based on dsm-iv-tr * patients having minimal total score of 18 on the ham-d17 and minimal score of 2 on the item of "depressed mood" at the baseline. exclusion criteria: * patients with schizophrenia or any other psychotic disorder * patients with history or presence of bipolar disorder

Keywords: depression